Metocurine Iodide
7601-55-0COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3.[I-].[I-]DIGFQJFCDPKEPF-OIUSMDOTSA-LMetocurine iodide is an aromatic ether.
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Metocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of metocurine iodide. Repeated administration of maintenance doses of metocurine iodide has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.
Metocurine iodide antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.
Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants.
용도Neuromuscular blocking agent.
일반 설명Metocurine iodide, ( )-O,O -dimethylchondrocurarine diiodide (Metubine iodide),is prepared from natural crude curare by extracting the curarewith methanolic potassium hydroxide. When theextract is treated with an excess of methyl iodide, the ( )-tubocurarine is converted to the diquaternary dimethylether and crystallizes out as the iodide (see “TubocurarineChloride”). Other ethers besides the dimethyl ether havebeen made and tested. For example, the dibenzyl ether wasone third as active as tubocurarine chloride, and the diisopropylcompound had only one half the activity. For comparison,the dimethyl ether has approximately 4 times theactivity of tubocurarine chloride.The pharmacological action of this compound is the sameas that of tubocurarine chloride, namely, a nondepolarizingcompetitive blocking effect on the motor end plate of skeletalmuscles. It is considerably more potent than d-tubocurarine,however, and has the added advantage of exerting much lesseffect on respiration. The effect on respiration is not a significantfactor in therapeutic doses. Accidental overdosage iscounteracted best by forced respiration.
7601-55-0DTXSID9022944CHEMBL1739CHEBI:6901